Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017, Article ID 4537631, 4 pages
https://doi.org/10.1155/2017/4537631
Case Report

Successful Outcome of Low-Dose S-1 Used to Treat Buccal Squamous Cell Carcinoma

1Department of Dentistry, Oral and Maxillofacial, Plastic and Reconstructive Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan
2Department of Dentistry and Oral Surgery, Shinjo Tokushukai Hospital, Yamagata, Japan

Correspondence should be addressed to Kazuyuki Yusa; pj.ca.u-atagamay.di.dem@asuy-k

Received 19 April 2017; Accepted 30 May 2017; Published 18 July 2017

Academic Editor: Constantine Gennatas

Copyright © 2017 Kazuyuki Yusa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. R. Pauloski, J. A. Logemann, A. W. Rademaker et al., “Speech and swallowing function after oral and oropharyngeal resections: One‐year follow‐up,” Head & Neck, vol. 16, no. 4, pp. 313–322, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. N. P. Nguyen, S. Sallah, U. Karlsson, and J. E. Antoine, “Combined chemotherapy and radiation therapy for head and neck malignancies: Quality of life issues,” Cancer, vol. 94, no. 4, pp. 1131–1141, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Clavel, J. B. Vermorken, F. Cognetti et al., “Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: A phase III study of the EORTC head and neck cancer cooperative group,” Annals of Oncology, vol. 5, no. 6, pp. 521–526, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Guardiola, F. Peyrade, L. Chaigneau et al., “Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer,” European Journal of Cancer, vol. 40, no. 14, pp. 2071–2076, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Shirasaka, Y. Shimamato, H. Ohshimo et al., “Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators,” Anti-Cancer Drugs, vol. 7, no. 5, pp. 548–557, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Shirasaka, K. Nakano, T. Takechi et al., “Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats,” Cancer Research, vol. 56, no. 11, pp. 2602–2606, 1996. View at Google Scholar · View at Scopus
  7. Y. Akutsu, T. Kono, M. Uesato et al., “S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma,” Oncology (Switzerland), vol. 84, no. 5, pp. 305–310, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Koizumi, H. Narahara, T. Hara et al., “S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial,” The Lancet Oncology, vol. 9, no. 3, pp. 215–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Itoi, M. Takashima, H. Ishimasa, H. Murata, and K. Tomoda, “Adjuvant chemotherapy with TS-1 for head and neck cancer—side effect of two-week application followed by one-week rest regimen,” Gan to Kagaku Ryoho. Cancer & Chemotherapy, vol. 33, no. 5, pp. 617–620, 2006. View at Google Scholar · View at Scopus
  10. T. Browder, C. E. Butterfield, B. M. Kräling et al., “Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer,” Cancer Research, vol. 60, no. 7, pp. 1878–1886, 2000. View at Google Scholar · View at Scopus
  11. G. Klement, S. Baruchel, J. Rak et al., “Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity,” Journal of Clinical Investigation, vol. 105, no. 8, pp. R15–R24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Bocci and R. S. Kerbel, “Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect,” Nature Reviews Clinical Oncology, vol. 13, no. 11, pp. 659–673, 2016. View at Publisher · View at Google Scholar
  13. G. Allegrini, T. Di Desidero, M. T. Barletta et al., “Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers,” Angiogenesis, vol. 15, no. 2, pp. 275–286, 2012. View at Publisher · View at Google Scholar · View at Scopus